Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Stylus Medicine

Request full access

We are backed by RA Ventures and Khosla Ventures

Cambridge, United StatesFounded 2022Biotech & Life Sciences

About Stylus Medicine

Stylus Medicine, a biotechnology firm established in 2022, is focused on developing in vivo genetic medicines to address significant challenges in cell and gene therapy. The company emerged from stealth in May 2025 with $85 million in Series A financing, co-founded by RA Capital's healthcare incubator, Raven, and Khosla Ventures. The funding round also saw participation from new investors, including Chugai Venture Fund, Eli Lilly and Company, and Johnson & Johnson Innovation—JJDC.

The scientific foundation of Stylus Medicine is rooted in the work of its academic founders: Patrick Hsu, Ph.D., of the Arc Institute and UC Berkeley, and Stanford University professors Ami S. Bhatt, M.D., Ph.D., Michael C. Bassik, Ph.D., and Lacramioara Bintu, Ph.D. Their research, particularly Hsu's work on viral proteins called recombinases, forms the basis of the company's core technology. The leadership team includes Chairman and CEO Emile Nuwaysir, Ph.D., a veteran with over 25 years in cell and gene therapy, and Chief Scientific Officer Jason Fontenot, Ph.D., who brings experience from roles at Sangamo Therapeutics and Juno Therapeutics.

Stylus Medicine's business model centers on the development and eventual commercialization of a proprietary therapeutic platform. This platform uniquely combines engineered, therapeutic-grade recombinases with non-viral, cell-targeted lipid nanoparticle (LNP) delivery systems. The core of the technology is its ability to perform sequence-specific genome integration, allowing for the precise insertion of large, multi-kilobase genetic payloads directly within the patient's body (*in vivo*). This approach circumvents the complex and costly manufacturing processes associated with traditional *ex vivo* cell therapies, where a patient's cells are extracted, modified, and then reinfused. By simplifying the treatment workflow, Stylus aims to create scalable, "off-the-shelf" genetic therapies, thereby expanding patient access.

The company's initial focus is on the oncology market, specifically on developing *in vivo* CAR-T cell therapies. This involves delivering a recombinase and a DNA payload that encodes for a Chimeric Antigen Receptor (CAR) directly to a patient's T-cells using an LNP infusion. This process effectively turns the patient's own body into a CAR-T cell factory. The platform's modularity allows for the adaptation of CAR constructs to target different antigens, opening pathways to treat various cancer types. Beyond oncology, the technology's versatility holds potential for applications in treating autoimmune and other genetic diseases.

Source: Dealroom company data

At a glance

Status
Operational
Employees
46
Open positions
5
Dealroom signal
59.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing May 2025 $85M $340M Chugai Venture Fund · Khosla Ventures · RA Capital Management · Johnson & Johnson Innovation ↗
SPINOUTOther financing Dec 2022 $0 — University of California, Berkeley —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Stylus Medicine website traffic

Latest recorded traffic for Stylus Medicine is 3.9K monthly website visits, up 178.6% over the last three months.

Latest monthly visits3.9K 3-month web change+178.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Stylus Medicine in the Cambridge ecosystem

Live from Dealroom

The Stylus Medicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Other known investors1 additional known investor

  • University of California, Berkeley
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Stylus Medicine on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Stylus Medicine’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.